{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T06:48:01Z","timestamp":1790837281319,"version":"4.1.0"},"reference-count":56,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,8,9]],"date-time":"2020-08-09T00:00:00Z","timestamp":1596931200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bone"],"published-print":{"date-parts":[[2020,12]]},"DOI":"10.1016\/j.bone.2020.115579","type":"journal-article","created":{"date-parts":[[2020,8,11]],"date-time":"2020-08-11T12:42:48Z","timestamp":1597149768000},"page":"115579","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":54,"special_numbering":"C","title":["Novel therapeutic approaches for the treatment of achondroplasia"],"prefix":"10.1016","volume":"141","author":[{"given":"Laurence","family":"Legeai-Mallet","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ravi","family":"Savarirayan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.bone.2020.115579_bb0005","first-page":"2393","article-title":"Nosology and classification of genetic skeletal disorders: 2019 revision. American journal of medical genetics","volume":"179","author":"Mortier","year":"2019","journal-title":"Part A"},{"key":"10.1016\/j.bone.2020.115579_bb0010","doi-asserted-by":"crossref","first-page":"117","DOI":"10.2147\/TACG.S51485","article-title":"Optimal management of complications associated with achondroplasia","volume":"7","author":"Ireland","year":"2014","journal-title":"Appl. Clin. Genet."},{"issue":"9582","key":"10.1016\/j.bone.2020.115579_bb0015","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/S0140-6736(07)61090-3","article-title":"Achondroplasia","volume":"370","author":"Horton","year":"2007","journal-title":"Lancet (London, England)"},{"issue":"6494","key":"10.1016\/j.bone.2020.115579_bb0020","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/371252a0","article-title":"Mutations in the gene encoding fibroblast growth factor receptor-3 in achondroplasia","volume":"371","author":"Rousseau","year":"1994","journal-title":"Nature."},{"issue":"2","key":"10.1016\/j.bone.2020.115579_bb0025","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/0092-8674(94)90302-6","article-title":"Mutations in the transmembrane domain of FGFR3 cause the most common genetic form of dwarfism, achondroplasia","volume":"78","author":"Shiang","year":"1994","journal-title":"Cell"},{"issue":"2","key":"10.1016\/j.bone.2020.115579_bb0030","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1038\/ng0696-233","article-title":"Graded activation of fibroblast growth factor receptor 3 by mutations causing achondroplasia and thanatophoric dysplasia","volume":"13","author":"Naski","year":"1996","journal-title":"Nat. Genet."},{"issue":"1","key":"10.1016\/j.bone.2020.115579_bb0035","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1159\/000446958","article-title":"Height outcome of recombinant human growth hormone treatment in achondroplasia children: a meta-analysis","volume":"86","author":"Miccoli","year":"2016","journal-title":"Hormone research in paediatrics"},{"issue":"3","key":"10.1016\/j.bone.2020.115579_bb0040","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1586\/17434440.2015.1005604","article-title":"Precice intramedullary limb lengthening system","volume":"12","author":"Paley","year":"2015","journal-title":"Expert Review of Medical Devices"},{"issue":"6","key":"10.1016\/j.bone.2020.115579_bb0045","doi-asserted-by":"crossref","first-page":"a015958","DOI":"10.1101\/cshperspect.a015958","article-title":"Molecular mechanisms of fibroblast growth factor signaling in physiology and pathology","volume":"5","author":"Belov","year":"2013","journal-title":"Cold Spring Harb. Perspect. Biol."},{"issue":"3","key":"10.1016\/j.bone.2020.115579_bb0050","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1086\/302000","article-title":"Mutations in fibroblast growth-factor receptor 3 in sporadic cases of achondroplasia occur exclusively on the paternally derived chromosome","volume":"63","author":"Wilkin","year":"1998","journal-title":"Am. J. Hum. Genet."},{"issue":"6","key":"10.1016\/j.bone.2020.115579_bb0055","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/j.ajog.2018.07.017","article-title":"Best practice guidelines regarding prenatal evaluation and delivery of patients with skeletal dysplasia","volume":"219","author":"Savarirayan","year":"2018","journal-title":"Am. J. Obstet. Gynecol."},{"issue":"4","key":"10.1016\/j.bone.2020.115579_bb0060","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1002\/dvdy.24479","article-title":"Achondroplasia: development, pathogenesis, and therapy","volume":"246","author":"Ornitz","year":"2017","journal-title":"Developmental Dynamics: an official publication of the American Association of Anatomists"},{"key":"10.1016\/j.bone.2020.115579_bb0065","doi-asserted-by":"crossref","unstructured":"Pauli RM. Achondroplasia: a comprehensive clinical review. Orphanet J Rare Dis. 2019;14(1):1. Published 2019 Jan 3. doi:https:\/\/doi.org\/10.1186\/s13023-018-0972-6.","DOI":"10.1186\/s13023-018-0972-6"},{"issue":"2","key":"10.1016\/j.bone.2020.115579_bb0070","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1006\/dbio.1993.1040","article-title":"Unique expression pattern of the FGF receptor 3 gene during mouse organogenesis","volume":"155","author":"Peters","year":"1993","journal-title":"Dev. Biol."},{"issue":"24","key":"10.1016\/j.bone.2020.115579_bb0075","doi-asserted-by":"crossref","first-page":"4977","DOI":"10.1242\/dev.125.24.4977","article-title":"Repression of hedgehog signaling and BMP4 expression in growth plate cartilage by fibroblast growth factor receptor 3","volume":"125","author":"Naski","year":"1998","journal-title":"Development (Cambridge, England)"},{"issue":"8","key":"10.1016\/j.bone.2020.115579_bb0080","doi-asserted-by":"crossref","first-page":"4455","DOI":"10.1073\/pnas.96.8.4455","article-title":"A mouse model for achondroplasia produced by targeting fibroblast growth factor receptor 3","volume":"96","author":"Wang","year":"1999","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.bone.2020.115579_bb0085","doi-asserted-by":"crossref","first-page":"43220","DOI":"10.1038\/srep43220","article-title":"Knock-in human FGFR3 achondroplasia mutation as a mouse model for human skeletal dysplasia","volume":"7","author":"Lee","year":"2017","journal-title":"Sci. Rep."},{"issue":"11","key":"10.1016\/j.bone.2020.115579_bb0090","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1172\/JCI6690","article-title":"Gly369Cys mutation in mouse FGFR3 causes achondroplasia by affecting both chondrogenesis and osteogenesis","volume":"104","author":"Chen","year":"1999","journal-title":"J. Clin. Invest."},{"issue":"2","key":"10.1016\/j.bone.2020.115579_bb0095","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.bbadis.2008.11.010","article-title":"Activating Fgfr3 Y367C mutation causes hearing loss and inner ear defect in a mouse model of chondrodysplasia","volume":"1792","author":"Pannier","year":"2009","journal-title":"Biochim. Biophys. Acta"},{"issue":"1","key":"10.1016\/j.bone.2020.115579_bb0100","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1093\/hmg\/8.1.35","article-title":"A Lys644Glu substitution in fibroblast growth factor receptor 3 (FGFR3) causes dwarfism in mice by activation of STATs and ink4 cell cycle inhibitors","volume":"8","author":"Li","year":"1999","journal-title":"Hum. Mol. Genet."},{"issue":"12","key":"10.1016\/j.bone.2020.115579_bb0105","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1093\/hmg\/10.12.1255","article-title":"Highly activated Fgfr3 with the K644M mutation causes prolonged survival in severe dwarf mice","volume":"10","author":"Iwata","year":"2001","journal-title":"Hum. Mol. Genet."},{"issue":"5","key":"10.1016\/j.bone.2020.115579_bb0110","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1016\/j.bone.2010.07.020","article-title":"Delayed bone age due to a dual effect of FGFR3 mutation in Achondroplasia","volume":"47","author":"Pannier","year":"2010","journal-title":"Bone"},{"issue":"5","key":"10.1016\/j.bone.2020.115579_bb0115","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1172\/JCI83926","article-title":"Tyrosine kinase inhibitor NVP-BGJ398 functionally improves FGFR3-related dwarfism in mouse model","volume":"126","author":"Komla-Ebri","year":"2016","journal-title":"J. Clin. Invest."},{"issue":"11","key":"10.1016\/j.bone.2020.115579_bb0120","doi-asserted-by":"crossref","first-page":"2914","DOI":"10.1093\/hmg\/ddu004","article-title":"FGFR3 mutation causes abnormal membranous ossification in achondroplasia","volume":"23","author":"Di Rocco","year":"2014","journal-title":"Hum. Mol. Genet."},{"issue":"14","key":"10.1016\/j.bone.2020.115579_bb0125","first-page":"2997","article-title":"Meckel\u2019s and condylar cartilages anomalies in achondroplasia result in defective development and growth of the mandible","volume":"25","author":"Biosse Duplan","year":"2016","journal-title":"Hum. Mol. Genet."},{"issue":"4","key":"10.1016\/j.bone.2020.115579_bb0130","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1038\/ng0496-390","article-title":"Skeletal overgrowth and deafness in mice lacking fibroblast growth factor receptor 3","volume":"12","author":"Colvin","year":"1996","journal-title":"Nat. Genet."},{"issue":"6","key":"10.1016\/j.bone.2020.115579_bb0135","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1016\/S0092-8674(00)81069-7","article-title":"Fibroblast growth factor receptor 3 is a negative regulator of bone growth","volume":"84","author":"Deng","year":"1996","journal-title":"Cell"},{"issue":"5","key":"10.1016\/j.bone.2020.115579_bb0140","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1086\/508433","article-title":"A novel mutation in FGFR3 causes camptodactyly, tall stature, and hearing loss (CATSHL) syndrome","volume":"79","author":"Oydemir","year":"2006","journal-title":"Am. J. Hum. Genet."},{"issue":"7","key":"10.1016\/j.bone.2020.115579_bb0145","first-page":"1908","article-title":"A second family with CATSHL syndrome: confirmatory report of another unique FGFR3 syndrome. American journal of medical genetics","volume":"170","author":"Escobar","year":"2016","journal-title":"Part A"},{"key":"10.1016\/j.bone.2020.115579_bb0150","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/bs.ctdb.2018.11.020","article-title":"Fibroblast growth factors in skeletal development","volume":"133","author":"Ornitz","year":"2019","journal-title":"Curr. Top. Dev. Biol."},{"issue":"3","key":"10.1016\/j.bone.2020.115579_bb0155","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1016\/j.bbrc.2018.07.044","article-title":"The FGF2 aptamer inhibits the growth of FGF2-FGFR pathway driven lung cancer cells","volume":"503","author":"Hamamoto","year":"2018","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"11","key":"10.1016\/j.bone.2020.115579_bb0160","doi-asserted-by":"crossref","first-page":"1974","DOI":"10.1038\/mt.2016.158","article-title":"Dual therapeutic action of a neutralizing anti-FGF2 aptamer in bone disease and bone cancer pain","volume":"24","author":"Jin","year":"2016","journal-title":"Molecular Therapy: the journal of the American Society of Gene Therapy"},{"key":"10.1016\/j.bone.2020.115579_bb0165","doi-asserted-by":"crossref","unstructured":"Garcia, S., Dirat, B., Tognacci, T., Rochet, N., Mouska, X., Bonnafous, S., Patouraux, S., Tran, A., Gual, P., Le Marchand-Brustel, Y., Gennero, I., & Gouze, E. (2013). Postnatal soluble FGFR3 therapy rescues achondroplasia symptoms and restores bone growth in mice. Science translational medicine, 5(203), 203ra124.","DOI":"10.1126\/scitranslmed.3006247"},{"issue":"40","key":"10.1016\/j.bone.2020.115579_bb0170","doi-asserted-by":"crossref","first-page":"38194","DOI":"10.1074\/jbc.M303164200","article-title":"Human combinatorial Fab library yielding specific and functional antibodies against the human fibroblast growth factor receptor 3","volume":"278","author":"Rauchenberger","year":"2003","journal-title":"J. Biol. Chem."},{"issue":"10","key":"10.1016\/j.bone.2020.115579_bb0175","doi-asserted-by":"crossref","first-page":"4039","DOI":"10.1182\/blood-2005-10-4179","article-title":"The inhibitory anti-FGFR3 antibody, PRO-001, is cytotoxic to t(4;14) multiple myeloma cells","volume":"107","author":"Trudel","year":"2006","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.bone.2020.115579_bb0180","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1242\/dmm.024760","article-title":"Inhibition of fibroblast growth factor receptor 3-dependent lung adenocarcinoma with a human monoclonal antibody","volume":"9","author":"Yin","year":"2016","journal-title":"Dis. Model. Mech."},{"issue":"7","key":"10.1016\/j.bone.2020.115579_bb0185","doi-asserted-by":"crossref","first-page":"2941","DOI":"10.1182\/blood-2004-10-3913","article-title":"CHIR-258, a novel, multitargeted tyrosine kinase inhibitor for the potential treatment of t(4;14) multiple myeloma","volume":"105","author":"Trudel","year":"2005","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.bone.2020.115579_bb0190","doi-asserted-by":"crossref","first-page":"4316","DOI":"10.1073\/pnas.1800338116","article-title":"Fibroblast growth factor receptor influences primary cilium length through an interaction with intestinal cell kinase","volume":"116","author":"Kunova Bosakova","year":"2019","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"10","key":"10.1016\/j.bone.2020.115579_bb0195","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0077652","article-title":"Fibroblast growth factor receptors as novel therapeutic targets in SNF5-deleted malignant rhabdoid tumors","volume":"8","author":"W\u00f6hrle","year":"2013","journal-title":"PLoS One"},{"issue":"5","key":"10.1016\/j.bone.2020.115579_bb0200","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1038\/bjc.2014.638","article-title":"mTOR inhibition improves fibroblast growth factor receptor targeting in hepatocellular carcinoma","volume":"112","author":"Scheller","year":"2015","journal-title":"Br. J. Cancer"},{"issue":"4","key":"10.1016\/j.bone.2020.115579_bb0205","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1002\/jbmr.1810","article-title":"Pharmacological inhibition of fibroblast growth factor (FGF) receptor signaling ameliorates FGF23-mediated hypophosphatemic rickets","volume":"28","author":"W\u00f6hrle","year":"2013","journal-title":"Journal of Bone and Mineral Research: the official journal of the American Society for Bone and Mineral Research"},{"issue":"2","key":"10.1016\/j.bone.2020.115579_bb0210","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1210\/en.2014-1914","article-title":"Meclozine promotes longitudinal skeletal growth in transgenic mice with achondroplasia carrying a gain-of-function mutation in the FGFR3 gene","volume":"156","author":"Matsushita","year":"2015","journal-title":"Endocrinology"},{"issue":"7519","key":"10.1016\/j.bone.2020.115579_bb0215","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1038\/nature13775","article-title":"Statin treatment rescues FGFR3 skeletal dysplasia phenotypes","volume":"513","author":"Yamashita","year":"2014","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.bone.2020.115579_bb0220","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.joca.2015.01.002","article-title":"A new prescription for growth? Statins, cholesterol and cartilage homeostasis","volume":"23","author":"Bush","year":"2015","journal-title":"Osteoarthr. Cartil."},{"issue":"7","key":"10.1016\/j.bone.2020.115579_bb0225","doi-asserted-by":"crossref","first-page":"4016","DOI":"10.1073\/pnas.071389098","article-title":"Dwarfism and early death in mice lacking C-type natriuretic peptide","volume":"98","author":"Chusho","year":"2001","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"1","key":"10.1016\/j.bone.2020.115579_bb0230","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1086\/422013","article-title":"Mutations in the transmembrane natriuretic peptide receptor NPR-B impair skeletal growth and cause acromesomelic dysplasia, type Maroteaux","volume":"75","author":"Bartels","year":"2004","journal-title":"American journal of human genetics"},{"issue":"12","key":"10.1016\/j.bone.2020.115579_bb0235","doi-asserted-by":"crossref","first-page":"E1988","DOI":"10.1210\/jc.2013-2358","article-title":"An activating mutation in the kinase homology domain of the natriuretic peptide receptor-2 causes extremely tall stature without skeletal deformities","volume":"98","author":"Hannema","year":"2013","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"7","key":"10.1016\/j.bone.2020.115579_bb0240","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1002\/humu.20511","article-title":"Overexpression of the C-type natriuretic peptide (CNP) is associated with overgrowth and bone anomalies in an individual with balanced t(2;7) translocation","volume":"28","author":"Bocciardi","year":"2007","journal-title":"Hum. Mutat."},{"issue":"12","key":"10.1016\/j.bone.2020.115579_bb0245","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1002\/humu.20611","article-title":"A cluster of translocation breakpoints in 2q37 is associated with overexpression of NPPC in patients with a similar overgrowth phenotype","volume":"28","author":"Moncla","year":"2007","journal-title":"Hum. Mutat."},{"issue":"1","key":"10.1016\/j.bone.2020.115579_bb0250","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1038\/nm971","article-title":"Overexpression of CNP in chondrocytes rescues achondroplasia through a MAPK-dependent pathway","volume":"10","author":"Yasoda","year":"2004","journal-title":"Nat. Med."},{"issue":"7","key":"10.1016\/j.bone.2020.115579_bb0255","doi-asserted-by":"crossref","first-page":"3138","DOI":"10.1210\/en.2008-1676","article-title":"Systemic administration of C-type natriuretic peptide as a novel therapeutic strategy for skeletal dysplasias","volume":"150","author":"Yasoda","year":"2009","journal-title":"Endocrinology"},{"issue":"6","key":"10.1016\/j.bone.2020.115579_bb0260","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1016\/j.ajhg.2012.10.014","article-title":"Evaluation of the therapeutic potential of a CNP analog in a Fgfr3 mouse model recapitulating achondroplasia","volume":"91","author":"Lorget","year":"2012","journal-title":"Am. J. Hum. Genet."},{"issue":"1","key":"10.1016\/j.bone.2020.115579_bb0265","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1124\/jpet.114.218560","article-title":"Neutral endopeptidase-resistant C-type natriuretic peptide variant represents a new therapeutic approach for treatment of fibroblast growth factor receptor 3-related dwarfism","volume":"353","author":"Wendt","year":"2015","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"1","key":"10.1016\/j.bone.2020.115579_bb0270","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1056\/NEJMoa1813446","article-title":"C-type natriuretic peptide analogue therapy in children with achondroplasia","volume":"381","author":"Savarirayan","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bone.2020.115579_bb0275","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1016\/S0140-6736(20)31541-5","article-title":"Once-daily, subcutaneous vosoritide therapy in children with achondroplasia: a randomised, double-blind, phase 3, placebo-controlled, multicentre trial","volume":"396","author":"Savarirayan","year":"2020","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.bone.2020.115579_bb0280","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1186\/s13023-020-01415-7","article-title":"Best practice guidelines for management of spinal disorders in skeletal dysplasia","volume":"15","author":"White","year":"2020","journal-title":"Orphanet Journal of Rare Diseases"}],"container-title":["Bone"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S8756328220303598?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S8756328220303598?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T17:53:27Z","timestamp":1757613207000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S8756328220303598"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12]]},"references-count":56,"alternative-id":["S8756328220303598"],"URL":"https:\/\/doi.org\/10.1016\/j.bone.2020.115579","relation":{},"ISSN":["8756-3282"],"issn-type":[{"value":"8756-3282","type":"print"}],"subject":[],"published":{"date-parts":[[2020,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Novel therapeutic approaches for the treatment of achondroplasia","name":"articletitle","label":"Article Title"},{"value":"Bone","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bone.2020.115579","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"115579"}}